Dark Forest Capital Management LP Sells 11,536 Shares of Arcellx, Inc. (NASDAQ:ACLX)

Dark Forest Capital Management LP reduced its position in shares of Arcellx, Inc. (NASDAQ:ACLX - Free Report) by 41.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,067 shares of the company's stock after selling 11,536 shares during the period. Dark Forest Capital Management LP's holdings in Arcellx were worth $1,232,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in ACLX. Gilead Sciences Inc. bought a new stake in shares of Arcellx in the fourth quarter worth $515,418,000. FMR LLC grew its position in shares of Arcellx by 22.8% in the 4th quarter. FMR LLC now owns 7,956,633 shares of the company's stock valued at $610,194,000 after buying an additional 1,477,360 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Arcellx by 35.3% in the fourth quarter. Vanguard Group Inc. now owns 3,330,092 shares of the company's stock valued at $255,385,000 after buying an additional 867,996 shares during the period. Capital World Investors bought a new position in shares of Arcellx during the fourth quarter worth about $19,393,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Arcellx by 156.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 305,088 shares of the company's stock worth $23,400,000 after acquiring an additional 186,013 shares during the period. Institutional investors own 96.03% of the company's stock.

Insider Activity

In related news, insider Christopher Heery sold 10,155 shares of Arcellx stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $63.79, for a total value of $647,787.45. Following the sale, the insider now owns 37,486 shares of the company's stock, valued at approximately $2,391,231.94. The trade was a 21.32 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Kavita Patel sold 1,500 shares of the company's stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $64.57, for a total value of $96,855.00. The disclosure for this sale can be found here. Insiders sold a total of 54,455 shares of company stock valued at $3,408,458 in the last ninety days. 6.24% of the stock is currently owned by insiders.

Arcellx Price Performance

Shares of ACLX traded up $0.01 during trading hours on Tuesday, hitting $64.56. 53,118 shares of the stock were exchanged, compared to its average volume of 553,443. The firm has a market capitalization of $3.56 billion, a P/E ratio of -91.01 and a beta of 0.33. The business has a 50-day moving average of $64.76 and a 200-day moving average of $74.65. Arcellx, Inc. has a fifty-two week low of $47.88 and a fifty-two week high of $107.37.

Arcellx (NASDAQ:ACLX - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.24). Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%. The company had revenue of $15.27 million for the quarter, compared to the consensus estimate of $27.42 million. As a group, analysts forecast that Arcellx, Inc. will post -1.58 earnings per share for the current fiscal year.

About Arcellx

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).